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Background: Silver nanoparticles (AgNPs) inhibit the proliferation of various fungi; how-
ever, their mechanisms of action remain poorly understood. To better understand the inhibi-
tory mechanisms, we focused on the early events elicited by 5 nm AgNPs in pathogenic
Candida albicans and non-pathogenic Saccharomyces cerevisiae.
Methods: The effect of 5 nm and 100 nm AgNPs on fungus cell proliferation was analyzed
by growth kinetics monitoring and spot assay. We examined cell cycle progression, reactive
oxygen species (ROS) production, and cell death using ﬂow cytometry. Glucose uptake was
assessed using tritium-labeled 2-deoxyglucose.
Results: The growth of both C. albicans and S. cerevisiaewas suppressed by treatment with 5 nm
AgNPs but not with 100 nm AgNPs. In addition, 5 nm AgNPs induced cell cycle arrest and
a reduction in glucose uptake in both fungi after 30 minutes of culture in a dose-dependent manner
(P<0.05). However, inC. albicans only, an increase in ROS productionwas detected after exposure
to 5 nm AgNPs. Concordantly, an ROS scavenger blocked the effect of 5 nm AgNPs on the cell
cycle and glucose uptake in C. albicans only. Furthermore, the growth-inhibition effect of 5 nm
AgNPs was not greater in S. cerevisiae mutant strains deﬁcient in oxidative stress response genes
than it was in wild type. Finally, 5 nm AgNPs together with a glycolysis inhibitor, 3-bromopyr-
uvate, synergistically enhanced cell death in C. albicans (P<0.05) but not in S. cerevisiae.
Conclusion: AgNPs exhibit antifungal activity in a manner that may or may not be ROS
dependent, according to the fungal species. The combination of AgNPs with 3-bromopyr-
uvate may be more useful against infection with C. albicans.
Keywords: metal nanoparticles, yeasts, anti-infective agents, antimetabolites
Introduction
Silver nanoparticles (AgNPs) are deﬁned as silver-containing particles with
a diameter of 1–100 nm and are produced through chemical, physical, or biological
methods.1 Silver precursors such as silver nitrate are reduced to AgNPs by chemical
reducing agents (eg, borohydride) or by physical techniques (eg, heating in an
oxygen-restricted environment).1 AgNPs are biologically synthesized by the reduc-
tion of silver ions using biological reducing agents (eg, enzymes).1 The biological
synthesis of AgNPs is called green synthesis as it does not utilize toxic chemicals as
reducing agents, but instead uses proteins, nucleotides, and carbohydrates produced
by plants, microorganisms, or algae.2
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AgNPs exert anticancer and antimicrobial activities.3
The cytotoxicity of AgNPs has been observed in various
human cancer cells including colon cancer, glioblastoma,
lung cancer, breast cancer, and acute myeloid leukemia.1,4
The antibacterial activities of AgNPs have been demon-
strated against various pathogenic Gram-positive and
Gram-negative bacteria.5–7 AgNPs even inhibit the growth
of antibiotic-resistant pathogens such as Bacillus cereus,
Staphylococcus aureus, Klebsiella pneumoniae, and
Pseudomonas aeruginosa.8 AgNPs also suppress the
growth of various pathogenic fungi such as Candida,
Aspergillus, and Cryptococcus species.9,10 Even antifungal
drug-resistant Candida albicans was killed by AgNPs.11
AgNPs have potential applications in the treatment of
cancer and infectious diseases.
The antifungal mechanisms of AgNPs remain to be
elucidated. Treating C. albicans with AgNPs for 24
hours leads to cell wall damage and disruption.12,13
AgNPs have been reported to exert toxicity through an
increase in reactive oxygen species (ROS) production;
however, this is still subject to debate. ROS are involved
in the AgNP-induced cell death of C. albicans, although
ROS scavengers do not completely suppress the cytotoxic
activity of AgNP on C. albicans.14,15 In S. cerevisiae, the
toxicity of AgNPs was not attributed to oxidative stress
response or increased cell wall/membrane permeability,
based on testing with single-gene mutant strains deﬁcient
in the ability to detoxify ROS or maintain cell wall/mem-
brane integrity.16 However, the role of genes regulating the
various stress responses, such as mitogen-activated protein
kinase (MAPK) HOG1, oxidative stress-activated tran-
scription factors, SKN7 and YAP1, and the cell wall integ-
rity maintaining factor, MAPK SLT2, in the antifungal
activity of AgNPs has not been well studied.17–21
Furthermore, we noted that AgNP-mediated structural
changes and ROS generation in yeast cells were mostly
observed 3–24 hours after the exposure to AgNPs in vitro.
In this study, we focused on the early events and ROS
generation induced by 5 nm AgNPs in C. albicans and
S. cerevisiae. We observed the cell cycle delay, reduced
glucose uptake, and increased ROS production in
C. albicans after 30 minutes' exposure to AgNPs.
Similarly, 5 nm AgNPs inhibited the growth, cell cycle
progression, and glucose uptake of S. cerevisiae; however,
increases in ROS production and cell death were not
observed in S. cerevisiae. Furthermore, we showed that
ROS may contribute to the antifungal activity of AgNPs
against C. albicans but not against S. cerevisiae.
Materials and methods
AgNPs and chemical reagents
Polyvinylpyrrolidone (PVP)-coated AgNPs of mean sizes
5 and 100 nm were purchased from I&C Technology
(Seoul, Republic of Korea). Characterization of AgNPs
was carried out as previously reported.22 In brief, using
transmission electron microscopy (model JEM-1011;
JEOL, Tokyo, Japan), the mean size was determined as
7.9±5.3 nm for 5 nm AgNPs and 70.9±71.3 nm for 100 nm
AgNPs. By dynamic light scattering analysis (Malvern
Instruments, Novato, CA, USA), the average size of
AgNPs was determined as 3.7 nm for 5 nm AgNPs and
95.9 nm for 100 nm AgNPs. N-acetylcysteine (NAC),
3-bromopyruvate (BrPA), and nocodazole were purchased
from Sigma-Aldrich (St Louis, MO, USA). Propidium
iodide was purchased from Merck Millipore (Billerica,
MS, USA). Cell-permeable reagents 2ʹ,7ʹ-dichloroﬂuores-
cein diacetate (DCFDA) and MitoSOX Red were pur-
chased from Molecular Probes (Eugene, OR, USA).
Yeast strains and AgNPs treatment
conditions
Candida albicans was provided by the National Culture
Collection for Pathogens (Cheongju-si, Republic of Korea).
Wild-type and six deletion mutants (△skn7,△yap1,△skn7
and △yap1 double mutant, △hog1, △SLT2, and △hog1
and △SLT2 double mutant) of S. cerevisiae BY4741 were
purchased from Invitrogen (Carlsbad, CA, USA).
Candida albicans was grown in Sabouraud dextrose
broth at 37°C for 6 hours on a rotary shaker at 140 rpm.
The culture was diluted with fresh medium until it exhib-
ited an OD of 0.1 at 600 nm and then either 5 nm or 100
nm AgNPs were added to the culture to a ﬁnal concentra-
tion of 2, 20, or 50 μg/mL. Each S. cerevisiae strain was
plated on YPD (1% yeast extract, 2% peptone, and 2%
dextrose) agar medium and incubated at 30°C for 2 days.
Then, a single colony was cultured in the YPD broth at
30°C for 1 day in the shaker at 140 rpm. The culture was
diluted with fresh medium to an OD600 of 0.1 and then
either 5 nm or 100 nm AgNPs were added to the culture to
a ﬁnal concentration of 2, 20, or 50 μg/mL.
Cell growth analysis
Candida albicans and S. cerevisiae were cultured in the
presence or absence of AgNPs as described in “Yeast strains
and AgNPs treatment conditions”, for 12 and 28 hours,
respectively. The absorbance of the culture at 600 nm was
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measured every 2 hours in the case of C. albicans or 4 hours
in the case of S. cerevisiae using a Beckman-Coulter (Brea,
CA) DU730 spectrophotometer. After 12 hours of culture of
C. albicans, a spot assay was performed by inoculating 5 μL
of each 10-fold serially diluted culture on Sabouraud dex-
trose agar plates and then incubating them at 37°C for 2 days.
Similarly, after 20 hours of culture time of S. cerevisiae,
a spot assay was performed by inoculating 5 μL of each 10-
fold serially diluted culture on the YPD agar plates and then
incubating them at 30°C for 2 days.
Cell death analysis
Candida albicans and S. cerevisiae were cultured in the
presence or absence of AgNPs as described in “Yeast
strains and AgNPs treatmentconditions” for 24 hours. In
the glycolysis inhibitor condition, BrPA co-treatment
along with AgNPs, BrPA was added to the culture to
a ﬁnal concentration of 20, 80, or 200 μM. After 2, 4, 6,
and 24 hours, 1 mL of the culture was centrifuged at
11,400×g for 5 minutes and the harvested cells were
washed twice with PBS. The cells were labeled with
propidium iodide (250 ng/mL) in PBS for 30 minutes at
room temperature and then analyzed using a FACSCanto
II (BD Biosciences, San Diego, CA, USA).
Cell cycle analysis
Candida albicans and S. cerevisiae were cultured in the pre-
sence of AgNPs as described in “Yeast strains and AgNPs
treatmentconditions”. As a positive control for cell cycle ana-
lysis, C. albicans was cultured in the presence of a cell cycle
arresting agent, nocodazole, with a ﬁnal concentration of 15
μg/mL. At 30 minutes and 1, 2, and 4 hours, cells were
harvested by centrifugation of 1 mL culture at 11,400×g for 5
minutes. The cells were washed twice with PBS, ﬁxed in 75%
ethyl alcohol, and then incubated in 200 μL of PBS containing
100 μg/mL of RNase A for 3 hours at 37°C. After washing
twice with PBS, the cells were resuspended in 200 μL of PBS
containing propidium iodide (10 μg/mL), and then incubated
for 4 hours at room temperature. The cell cycle was analyzed
using a ﬂow cytometer. In the case of the ROS scavenger co-
treatment, NAC was added to the culture to a ﬁnal concentra-
tion of 5 mM and 1 hour later AgNPs were added.
Analysis of glucose uptake
Candida albicans and S. cerevisiae were cultured as
described in “Yeast strains and AgNPs treatmentconditions”
and diluted with fresh media containing half the amount of
dextrose of the original Sabouraud dextrose broth and YPD
broth, respectively, to an OD600 of 0.2. Candida albicans
and S. cerevisiae were cultured for 1 hour at 37°C and at
30°C, respectively, in the presence or absence of 5 mM
NAC. Then, 5 nm AgNPs and tritium-labeled 2-deoxyglu-
cose (2-DG) (ﬁnal 2.5 μCi/mL; Perkin Elmer, Boston, MA,
USA) were added to the culture. After 30 minutes, the cells
in 1 mL of culture were harvested by centrifugation and
washed three times with cold PBS containing the glucose
transporter inhibitor cytochalasin B (2.5 μg/mL; Sigma-
Aldrich) by centrifugation at 11,400×g, at 4°C for 5 min-
utes. The cells were then lysed in 400 μL RIPA buffer
containing 1% SDS and mixed with 8 mL of scintillation
solution. The radioactive count was determined using
a liquid scintillation analyzer (Perkin Elmer).
Analysis of ROS production
Candida albicans and S. cerevisiae were treated with AgNPs
for 30 minutes as described in “Yeast strains and AgNPs
treatmentconditions”. When the ROS scavenger was
included, NAC (ﬁnal concentration of 5 mM) was added
into the culture and 1 hour later AgNPs were added. As
a positive control, the ROS inducer H2O2 was added to the
culture of C. albicans and S. cerevisiae to a ﬁnal concentra-
tion of 100 μM and 580 μM, respectively, and then incubated
for 30 minutes. The cells were then harvested and washed in
PBS twice by centrifugation at 11,400×g, at 4°C for 5 min-
utes. The cells were resuspended in PBS and labeled with
cellular ROS-indicating ﬂuoroprobe DCFDA (5 μM) for 30
minutes or mitochondrial superoxide indicator MitoSOX
Red (2 μM) for 10 minutes at 37°C. The cells were washed
three times, and the geometric mean ﬂuorescence intensity
(gMFI) of the cells was measured using ﬂow cytometry.
Statistical analysis
The Kruskal–Wallis test with Dunn’s multiple comparison
test was used for evaluating the differences among three or
more groups. Two-way ANOVA with Bonferroni correc-
tion was used to analyze the difference between two
groups. Differences were considered signiﬁcant when the
P-value was lower than 0.05.
Results
Treatment with 5 nm AgNPs inhibits cell
proliferation of both C. albicans and
S. cerevisiae
We ﬁrst analyzed the effect of various concentrations of 5 nm
and 100 nm AgNPs on the proliferation of C. albicans and
Dovepress Lee et al
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S. cerevisiae. Compared to the control (culture without
AgNPs), C. albicans proliferation signiﬁcantly decreased in
the presence of 20 μg/mL or 50 μg/mL of 5 nm AgNPs;
however, cell proliferationwas not affected in the presence of
2 μg/mL of 5 nm AgNPs or at any concentration of 100 nm
AgNPs (Figure 1A) (P<0.005). A spot assay using a 12-hour
culture showed concordant results (Figure 1C). Similarly,
S. cerevisiae proliferation was suppressed in the presence
of 20 μg/mL or 50 μg/mL of 5 nm AgNPs (Figure 1B);
however, it was not affected in the presence of 2 μg/mL of
5 nm AgNPs or any concentration of 100 nm AgNPs
(P<0.005). A spot assay using a 20-hour culture showed
concordant results (Figure 1D).
Treatment with 5 nm AgNPs enhances
cell death in C. albicans but not in
S. cerevisiae
We then examined cell death in AgNP-treated C. albicans
and S. cerevisiae cultures (Figure 2). The cell death
frequency in C. albicans in the presence of 50 μg/mL of
5 nm AgNPs was signiﬁcantly increased at 2, 4, 6, and 24
hours compared to that of the control (Figure 2A)
(P<0.05). The cell death frequency in C. albicans treated
with 20 μg/mL of 5 nm AgNPs was also increased com-
pared to that of the control but statistical signiﬁcance was
observed only at 6 and 24 hours (P<0.05). In the case of
the cell death frequency in C. albicans treated with 2 μg/
mL of 5 nm AgNPs, a statistically signiﬁcant increase was
found only at 6 hours compared to that of the control
(P<0.05). The cell death frequency in C. albicans in the
presence of 20 and 50 μg/mL of 5 nm AgNPs increased
with time, whereas in the presence of 2 μg/mL of AgNPs it
decreased at 24 hours, probably owing to the proliferation
of live C. albicans. The treatment of C. albicans with 100
nm AgNPs did not the change cell death frequency com-
pared to that of the control (Figure 2A). In contrast to
C. albicans, there was no signiﬁcant difference in the cell
death frequency in S. cerevisiae cultured in the presence of
5 nm and 100 nm AgNPs for 2–24 hours, compared to that
100 nm
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Figure 1 Growth inhibition of Candida albicans and Saccharomyces cerevisiae after treatment with 5 nm AgNPs. (A) Growth kinetics and (C) spot assay of C. albicans in either the
absence or presence of 5 nm or 100 nm AgNPs (2, 20, and 50 μg/mL). The C. albicans culture was diluted with fresh Sabouraud dextrose broth and cultured for 12 hours at 37°C.
Spot assay was performed by inoculation of 10-fold serial dilutions of 12-hour culture on the Sabouraud dextrose agar plates. (B) Growth kinetics and (D) spot assay of S. cerevisiae
in either the absence or presence of 5 nm or 100 nmAgNPs. The S. cerevisiae culture was diluted with fresh YPD broth and cultured for 20 hours at 30°C. Spot assay was performed
by inoculation of 10-fold serial dilutions of 20-hour culture on the YPD agar plates. Cell growth was measured at 600 nm. Control consists of yeast cells not treated with AgNPs.
Data are presented as mean ± SD from two independent experiments performed in triplicate. **P<0.005, ***P<0.001 vs control and vs cells treated with 100 nm AgNPs.
Abbreviations: AgNPs, silver nanoparticles; BrPA, 3-bromopyruvate; YPD, 1%yeast extract, 2% peptone, and 2% dextrose.
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Figure 2 Enhanced cell death in Candida albicans but not in Saccharomyces cerevisiae in the presence of 5 nm AgNPs. Representative histograms of 6-hour culture and cell
death frequency of (A) C. albicans and (B) S. cerevisiae in either the presence or absence of 5 nm or 100 nm AgNPs at 2, 4, 6, and 24 hours of culture. Data are presented as
mean ± SD from two independent experiments performed in triplicate. *P<0.05, **P<0.005, ***P<0.001.
Abbreviations: AgNPs, silver nanoparticles; PI, propidium iodide.
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of the control (Figure 2B). These results showed
a differential effect of 5 nm AgNPs on cell death in
C. albicans and S. cerevisiae, indicating that cell death
could not account for the AgNP-mediated growth suppres-
sion in S. cerevisiae.
Treatment with 5 nm AgNPs delays cell
cycle progression of both C. albicans and
S. cerevisiae at G1 phase
We next evaluated the effect of AgNPs on the cell cycle
progression. In this experiment, we included a positive con-
trol consisting of cells treated with nocodazole, which had an
increased G2 phase cell frequency of C. albicans at 2 hours
compared to the untreated control culture (Figure 3A). When
C. albicans was exposed to 5 nm AgNPs, the cell cycle was
arrested in G1 phase in a dose-dependent manner (Figure 3B
and D). The G1 phase cell frequency of control culture of
C. albicans (in the absence of AgNPs) was over 80% at the
beginning of culture, which then decreased to approximately
60% and 40% at 0.5 and 1 hour, respectively. The time-
dependent alteration in G1 phase cell frequency of the culture
in the presence of 100 nm AgNPs was similar to that of
control culture (Figure 3D). However, the G1 phase cell
frequencies, in culture treated with 2 μg/mL of 5 nm
AgNPs, were transiently but signiﬁcantly increased after 30
minutes compared to control culture (Figure 3D) (P<0.05).
Further, the G1 phase cell frequencies in the presence of both
20 and 50 μg/mL of 5 nm AgNPs were signiﬁcantly higher
from 1 to 4 hour of culture compared to control, even though
there was an exception that no statistical signiﬁcance was
observed at 2 hours after 20 μg/mL AgNP treatment (Figure
3D) (P<0.05). Similarly, the G1 phase cell frequencies for
S. cerevisiaewere signiﬁcantly higher in the presence of both
20 and 50 μg/mL of 5 nm AgNPs at 0.5, 1, 2, and 4 hours
compared to control culture but were not different in the
presence of 100 nm AgNPs (Figure 3C and E) (P<0.05).
These results demonstrate that treatment with 5 nm AgNPs
may lead to G1 phase delay of C. albicans and S. cerevisiae.
Treatment with 5 nm AgNPs decreases
glucose uptake in C. albicans and
S. cerevisiae
We then examined whether 5 nm AgNPs alter the glucose
uptake of C. albicans and S. cerevisiae (Figure 4). As we
had earlier observed a 5 nm AgNP-mediated cell cycle
delay of 30 minutes, we assessed glucose uptake for 30
minutes after AgNP treatment. Although the G1 cell cycle
delay observed 30 minutes after treatment was similar for
cultures treated with 2, 20, and 50 μg/mL 5 nm AgNPs,
glucose uptake was signiﬁcantly reduced only in the pre-
sence of 50 μg/mL 5 nm AgNPs compared to the control
(P<0.05). Although we could not determine whether the
alteration in glucose uptake was the cause or the conse-
quence of AgNP-induced G1 cell cycle delay, these results
showed similar effects of 5 nm AgNPs on the glucose
uptake in C. albicans and S. cerevisiae.
Treatment with 5 nm AgNPs increases
ROS production in C. albicans but not in
S. cerevisiae
We then investigated the ROS production in C. albicans
and S. cerevisiae in the presence of 5 nm AgNPs. We ﬁrst
assessed intracellular ROS levels using DCFDA labeling
(Figure 5). Compared to control, gMFI, representing ROS
levels, was signiﬁcantly increased in C. albicans in the
presence of 2, 20, and 50 μg/mL AgNPs at 30 minutes
(Figure 5A and C) (P<0.05) and was downregulated by the
co-presence of AgNPs and an ROS scavenger, NAC
(Figure 5E) (P<0.05). However, gMFI was not increased
in S. cerevisiae in the presence of 5 nm AgNPs (Figure 5B
and D). Moreover, gMFI was similar for the untreated and
NAC-treated S. cerevisiae (Figure 5F). We next examined
mitochondrial ROS production by MitoSOX Red labeling.
Increased gMFI was observed in C. albicans cultured for
30 minutes in the presence of 20 and 50 μg/mL AgNPs
(Figure 6A and C) (P<0.05), whereas gMFI was decreased
in the co-presence of AgNPs and NAC (Figure 6E)
(P<0.005). In contrast, gMFI in S. cerevisiae was not
increased in the presence of AgNPs (Figure 6B and D),
and it was decreased when NAC was also present at 2 or
20 μg/mL of AgNPs (Figure 6F). These results suggest
that treatment with 5 nm AgNPs induced ROS production
in C. albicans but not in S. cerevisiae, at least during the
initial 30 minutes of culture time.
Inhibitory effect of 5 nm AgNPs on cell
growth is similar between S. cerevisiae
wild type and S. cerevisiae mutants
harboring deletion of oxidative or cell
wall stress response genes
To further elucidate whether ROS are involved in the sup-
pressive effect of 5 nm AgNPs on S. cerevisiae growth, we
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investigated the proliferation of S. cerevisiae wild-type
BY4741 and deletion mutants with mutations in one or
two genes involved in the oxidative or cell wall damage
response in the presence of 5 nm AgNPs. If ROS production
were important for the AgNP effect, the AgNP-mediated
growth inhibition would have been greater in the mutants
than in the wild-type strain. Compared to the control (with-
out AgNPs), the growth of the deletion mutants SKN7,
YAP1, HOG1, and SLT2, as well as wild-type strain
BY4741, was signiﬁcantly suppressed in the presence of
10, 20, and 50 μg/mL of 5 nm AgNPs, but not in the
presence of 2 μg/mL of 5 nm or 2 to 50 μg/mL of 100 nm
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AgNPs (Figure 7A) (P<0.005). The growth kinetics as well
as the spot assay results showed that the inhibitory effects of
5 nm AgNPs on the deletion mutants SKN7, YAP1, HOG1,
and SLT2 were similar to the effects on the wild-type strain
BY4741 (Figure 7A and B). These results suggest that the
expression of SKN7, YAP1,HOG1, or SLT2 genes, as well as
ROS production, may not be pivotal for the 5 nm AgNP-
mediated growth suppression in S. cerevisiae.
Treatment with ROS scavenger reduces
G1 phase cell frequency in C. albicans
exposed to 5 nm AgNPs but not in
S. cerevisiae
As there was a signiﬁcant increase in ROS production in 5
nm AgNP-treated C. albicans but not in S. cerevisiae, we
speculated that an ROS scavenger could restore cell cycle
progression in C. albicans but not in S. cerevisiae. Thus, we
examined the cell cycles of C. albicans and S. cerevisiae
pretreated with 5 mM NAC, and then treated with 5 nm
AgNPs (Figure 8). As expected, G1 phase cell frequency,
which was increased in the presence of 5 nm AgNPs alone,
was signiﬁcantly reduced after treatment with NAC in
C. albicans (Figure 8A) (P<0.005). However, NAC treat-
ment did not decrease G1 phase cell frequency in
S. cerevisiae treated with 5 nm AgNPs (Figure 8B). These
results support our presumption that 5 nm AgNP-induced
ROS production leads to G1 phase delay in C. albicans and
that ROS production is not involved in AgNP-mediated G1
phase delay in S. cerevisiae.
Treatment with ROS scavenger restores
glucose uptake in 5 nm AgNP-treated
C. albicans
We next investigated whether an ROS scavenger could
restore glucose uptake in AgNP-treated C. albicans and
S. cerevisiae. We assessed the glucose uptake of
C. albicans and S. cerevisiae pretreated with 5 mM NAC
for 1 hour, and then treated with 5 nm AgNPs for 30
minutes. Glucose uptake was signiﬁcantly increased in
C. albicans in the co-presence of NAC and AgNPs com-
pared to that in the presence of AgNPs alone (Figure 9A)
(P<0.005). However, glucose uptake in S. cerevisiae co-
treated with NAC and AgNPs was not signiﬁcantly
increased compared to that in S. cerevisiae treated with
AgNPs alone (Figure 9B). These results indicate that
AgNP-induced ROS production may be responsible for
the reduction of glucose uptake in C. albicans but not in
S. cerevisiae.
Treatment with 5 nm AgNPs and
a glycolysis inhibitor, bromopyruvate,
synergistically enhances cell death in
C. albicans but not in S. cerevisiae
As treatment with 5 nm AgNPs reduced glucose uptake
in both C. albicans and S. cerevisiae, we investigated
whether inhibition of glucose consumption enhanced 5
nm AgNP-mediated cell death in C. albicans and
S. cerevisiae. Treatment with the glycolysis inhibitor
BrPA alone did not enhance cell death in C. albicans
or S. cerevisiae, compared to that of the untreated con-
trol (Figure 10A and B). As expected, 200 μM BrPA
treatment with 2 or 20 μg/mL of 5 nm AgNPs signiﬁ-
cantly increased cell death in C. albicans at 6 and 24
hours of culture time (Figure 10A) (P<0.05). In
C. albicans treated with 80 μM BrPA, cell death fre-
quency was signiﬁcantly elevated in the presence of 20
μg/mL of 5 nm AgNPs but not in the presence of 2 μg/
mL (Figure 10A) (P<0.05), indicating that BrPA treat-
ment upregulated AgNP-induced cell death in
C. albicans in a dose-dependent manner. However, the
synergistic cytotoxic effect of BrPA and 5 nm AgNPs
was not observed in S. cerevisiae (Figure 10B). Taken
together, these results show that 5 nm AgNPs differen-
tially regulated the growth and survival of C. albicans
and S. cerevisiae.
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Figure 4 Decrease in glucose uptake of Candida albicans and Saccharomyces cerevisiae
in the presence of 5 nm AgNPs. Glucose uptake of (A) C. albicans and (B) S. cerevisiae
treated with 5 nm AgNPs for 30 minutes. Data are presented as mean ± SD from two
independent experiments performed in triplicate. *P<0.05, **P<0.005.
Abbreviation: AgNPs, silver nanoparticles.
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Discussion
Previously, the growth suppression effect of AgNPs has
been consistently observed across diverse fungal spe-
cies, but the underlying mechanisms of action have
varied. In this study, we showed common and differen-
tial effects of 5 nm AgNPs in C. albicans and
S. cerevisiae; growth suppression, cell cycle delay, and
glucose uptake reduction were commonly observed in
both fungi, whereas the increase in ROS production and
cell death, as well as the synergic effect of 5 nm AgNPs
with BrPA, were observed only in C. albicans. Our
results also indicate that an ROS scavenger restored
the cell cycle progression and glucose uptake in
C. albicans treated with 5 nm AgNPs but not in
S. cerevisiae, suggesting different antifungal mechan-
isms of 5 nm AgNPs in the two species. Considering
this possibility, three main points raised from our results
are discussed.
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Figure 5 Increased cellular ROS production in Candida albicans in the presence of 5 nm AgNPs. Candida albicans (A, C, E) and Saccharomyces cerevisiae (B, D, F) were
cultured in the presence of 5 nm AgNPs for 30 minutes. Then, ROS levels were assessed using DCFDA labeling. NAC was added to the culture 1 hour prior to the addition
of AgNPs or H2O2 (100 μM for C. albicans and 580 μM for S. cerevisiae). Control consists of yeast cells not treated with AgNPs. Data are presented as mean ± SD from two
independent experiments performed in triplicate. *P<0.05, ***P<0.001.
Abbreviations: AgNPs, silver nanoparticles; DCFDA, 2ʹ,7ʹ-dichloroﬂuorescein diacetate; gMFI, geometric mean ﬂuorescence intensity; NAC, N-acetylcysteine; ROS,
reactive oxygen species.
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The ﬁrst discussion point is that 5 nm but not 100 nm
AgNPs inhibit the growth and cell cycle progression in both
C. albicans and S. cerevisiae. These results are concordant
with previous reports in that the size of AgNPs inﬂuences
biological effects such as cytotoxicity.23 In human cells,
smaller AgNPs exhibit greater toxicity.23 In addition, small-
size AgNPs in the range of 1–10 nm in diameter have the
advantage of binding to bacteria and viruses.24,25 We could
not ﬁnd a report that directly compared the impact of AgNP
size on the antifungal activity. However, the growth-
inhibition effect of AgNPs with sizes ranging from 3 nm
to 85 nm has been clearly demonstrated in various fungi,
including C. albicans and S. cerevisiae.14,16,26–28
Our ﬁndings that 5 nm AgNPs induced cell cycle arrest
in both C. albicans and S. cerevisiae corroborate the pre-
vious observation that AgNPs lead to cell cycle arrest in
human cancer cells as well as fungi.12–14,29 However, the
phase at which cells are arrested by treatment with AgNPs
is different depending on the study. In line with our results,
G1 phase arrest was demonstrated in A549 cells after
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Figure 6 Increased mitochondrial ROS production in Candida albicans in the presence of 5 nm AgNPs. Candida albicans (A, C, E) and Saccharomyces cerevisiae (B, D, F)
were cultured in the presence of 5 nm AgNPs for 30 minutes. Then, ROS levels were assessed using MitoSOX Red labeling. NAC was added to the culture 1 hour prior to
the addition of AgNPs or H2O2 (100 μM for C. albicans and 580 μM for S. cerevisiae). Control consists of yeast cells not treated with AgNPs. Data are presented as mean ±
SD from two independent experiments performed in triplicate. *P<0.05, **P<0.005, ***P<0.001.
Abbreviations: AgNPs, silver nanoparticles; gMFI, geometric mean ﬂuorescence intensity; NAC, N-acetylcysteine; ROS, reactive oxygen species.
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Figure 7 Growth inhibition in Saccharomyces cerevisiae deletional mutants treated with 5 nm AgNPs. (A) Growth kinetics and (B) spot assay results of S. cerevisiae wild-type
BY4741 and deletional mutants of the indicated genes in the presence or absence of AgNPs. Cell growth was analyzed by measuring OD600. Spot assay was performed by
inoculation of serial dilutions of 28-hour culture on the YPD agar plates. Control consists of yeast cells not treated with AgNPs. Data are presented as mean ± SD from two
independent experiments performed in triplicate. **P<0.005.
Abbreviations: AgNPs, silver nanoparticles; YPD, 1% yeast extract, 2% peptone, and 2% dextrose.
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treatment with AgNPs.30 However, the same A549 cells
were arrested at the G2/M phase by treatment with AgNPs
in a different study.31 In contrast to our results, Kim et al
reported that 3 nm AgNPs increased the G2/M phase cell
frequency in C. albicans.12 We do not know what deter-
mines the phase in cells treated with AgNPs; however,
there are several differences between the experimental
conditions in our study and those of Kim et al: PVP-
coated AgNPs vs uncoated AgNPs, culture at 37°C vs at
28°C, and cell cycle analysis time-points at 4 hours vs at 8
hours, respectively.12 To support our ﬁndings, we demon-
strated that nocodazole treatment increased G2/M phase
cell frequency in C. albicans and S. cerevisiae (Figure 3A,
and data not shown). Furthermore, we could restore
AgNP-induced G1 phase delay using an ROS scavenger,
NAC, and these results are in line with a report by Correia
et al showing that the ROS-inducing molecule H2O2 led to
a G1 phase delay in C. albicans.32
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Figure 8 An ROS scavenger restored AgNP-induced G1 phase delay in Candida albicans but not in Saccharomyces cerevisiae. G1 phase cell percentage was analyzed by ﬂow
cytometry in (A) C. albicans and (B) S. cerevisiae cultured in either the presence or absence of 5 nm AgNPs at the indicated time-points. NAC was added to the culture
1 hour prior to addition of AgNPs. Data are presented as mean ± SD from two independent experiments performed in triplicate. **P<0.005, ***P<0.001.
Abbreviations: AgNPs, silver nanoparticles; NAC, N-acetylcysteine; ROS, reactiveoxygen species.
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The second discussion point is that different mechan-
isms of action of AgNPs may work in C. albicans and
S. cerevisiae BY4741. We revealed that ROS may play
a role in AgNP-mediated growth suppression of
C. albicans but not of S. cerevisiae. This is supported by
three ﬁndings. First, there is increased ROS production
following treatment with 5 nm AgNPs in C. albicans but
not in S. cerevisiae (Figures 5 and 6). Second, cell cycle
progression and glucose uptake are restored by NAC co-
treatment with 5 nm AgNPs in C. albicans but not in
S. cerevisiae (Figures 8 and 9). Third, there is no increased
sensitivity to 5 nm AgNPs in S. cerevisiae mutants with
deletions in genes associated with ROS stress response,
such as HOG1, SKN7, YAP1, and SLT2, compared with
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Figure 9 An ROS scavenger restored AgNP-mediated glucose uptake reduction in Candida albicans. Glucose uptake of (A) C. albicans and (B) Saccharomyces cerevisiae after
culturing for 30 minutes in either the presence or absence of AgNPs. NAC was added to the culture 1 hour prior to addition of AgNPs. Data are presented as mean ± SD
from two independent experiments performed in triplicate. **P<0.005, ***P<0.001.
Abbreviations: AgNPs, silver nanoparticles; NAC, N-acetylcysteine; ROS, reactive oxygen species.
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Figure 10 Synergistic cytotoxicity of AgNPs with BrPA in Candida albicans. Cell death in (A) C. albicans and (B) Saccharomyces cerevisiae in the presence of BrPA, 5 nm
AgNPs, or a combination of both was analyzed using propidium iodide labeling at 6 and 24 hours. Data are presented as mean ± SD from two independent experiments
performed in triplicate. *P<0.05, **P<0.005, ***P<0.001.
Abbreviations: AgNPs, silver nanoparticles; BrPA, 3-bromopyruvate.
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wild-type S. cerevisiae BY4741 (Figure 7). Concordantly,
Hwang et al reported that treatment with 3 nm AgNPs
increased hydroxyl radical production, leading to reduced
mitochondrial membrane potential and to cell death in
C. albicans.14 Radhakrishnan et al speculated that both
ROS-dependent and ROS-independent pathways are
involved in the induction of cell death in C. albicans when
exposed to 10–30 nm citrate-reduced AgNPs.15,33 In addi-
tion, in ﬁssion yeast, the toxic effects of AgNPs are attrib-
uted to the generation of ROS through the release of Ag ions
inside the cells internalizing AgNPs.34 Consistent with our
results, no increase in ROS production in S. cerevisiae
BY4741 treated with 4–100 μg/mL PVP-coated AgNPs,15
and a similar effect of AgNPs on the growth of wild-type
and single-gene deletion mutants of S. cerevisiae defective
in oxidative stress defense (yap1Δ, sod1Δ, or sod2Δ) have
been reported.15 However, Sillapawattana et al observed
increased ROS production in S. cerevisiae BY4742 and
more prominent growth suppression in ctt1, sod2, or gsh2
deletion mutants compared to wild type when treated with
AgNPs.35 Of note, the discordance of our results with those
of Sillapawattana et al may be related to the difference in
S. cerevisiae strains and culture conditions. We used
S. cerevisiae BY4741, which is characterized by the
MATa and met15Δ phenotype, and cultured in YPD media
containing 2% glucose at 30°C, while Sillapawattana et al
used S. cerevisiae BY4742, which is characterized by the
MATα and lys2Δ phenotype, and cultured in complete
synthetic dropout medium containing 4% glucose at
28°C.35,36 More studies are required to further elucidate
the apparently inconsistent results obtained from
S. cerevisiae. Still, our results suggest ROS-dependent and
ROS-independent antifungal mechanisms of AgNPs,
according to the species and strain of fungi.
The third discussion point is the synergistic effect of
a glycolysis inhibitor, BrPA, on AgNP-induced cell
death in C. albicans. To the best of our knowledge, the
combinatorial effect of BrPA and AgNPs against fungi
has not been reported previously. Although BrPA was
reported as a frequently suppressive drug in the antifun-
gal drug pairs against S. cerevisiae, in that study AgNPs
were not included.37 Compared to previous reports eval-
uating the effect of BrPA alone on various fungi, we
used a relatively low concentration of BrPA.38,39 The
minimal inhibitory concentrations (MICs) for the clini-
cally isolated C. albicans were reported to be within
2.4–3.6 mM and the MIC for S. cerevisiae was
1.8 mM.38,39 We used much lower amounts of BrPA
(20, 80, and 200 μM), as we wanted to examine the
therapeutic potential of BrPA against Candida infection
at the concentration that minimized human cell death.
Our previous study found slightly decreased cell survival
of peripheral blood mononuclear cells at 80 μM of
BrPA.40 In this study, we demonstrated that both 80
and 200 μM of BrPA synergistically enhanced cell
death in C. albicans (Figure 10), thus revealing the
potential of the combination of AgNPs and BrPA as an
antifungal agent against C. albicans.
The synergic effect of BrPAwith AgNPs may be linked
with the increased ROS production and decreased glucose
uptake in C. albicans by treatment with AgNPs.
Previously, the main toxic effect of BrPA was suggested
to be intracellular ATP depletion, and BrPA efﬁcacy was
inversely correlated with intracellular levels of reduced
glutathione.39,41 Glucose is required for the production of
reduced glutathione through the pentose phosphate path-
way, and increased ROS production leads to the consump-
tion of reduced glutathione.42,43 It is conceivable that the
level of glutathione is reduced in AgNP-treated
C. albicans as a result of increased ROS production, and
thus, a synergic effect of BrPA and AgNPs was observed
in C. albicans. However, ROS production was not
increased after treatment of S. cerevisiae with AgNPs,
and, thus, no synergic effect of BrPA and the AgNPs
was observed in this yeast.
Conclusion
Our results demonstrate that AgNPs exert similar growth-
inhibition effects in C. albicans and S. cerevisiae, even though
the underlying mechanisms may be different. In addition, we
suggest that the antifungal activity of AgNPsmay be enhanced
by combination with an inhibitor of glucose metabolism.
Abbreviation list
AgNPs, silver nanoparticles; BrPA, 3-bromopyruvate;
DCFDA, dichloroﬂuorescein diacetate; 2-DG, deoxyglucose;
gMFI, geometric mean ﬂuorescence intensity; MAPK, mito-
gen-activated protein kinase; NAC, N-acetylcysteine; PBS,
phosphate-buffered saline; PVP, polyvinylpyrrolidone; ROS,
reactive oxygen species; YPD, 1% yeast extract, 2% peptone,
and 2% dextrose.
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